Analysis of the effectiveness of serpatinib in the treatment of advanced lung cancer

Selpercatinib (Selpercatinib) is a targeted drug targeting RET gene mutations. It is mainly used to treat advanced or metastatic lung cancer with RET gene rearrangements. RET gene rearrangement is a genetic mutation that can cause abnormal growth and spread of tumor cells. Serpatinib inhibits the growth and spread of tumors by inhibiting RET kinase activity and blocking abnormal signaling pathways.

Multiple clinical trials have proven the effectiveness of serpatinib in the treatment of advanced lung cancer. For example, in the LIBRETTO-001 clinical trial, serpatinib showed significant anti-tumor effects in patients with RET fusion-positive non-small cell lung cancer (NSCLC) who were newly treated and who had previously received platinum-based chemotherapy. The objective response rate (ORR) of patients in the treatment-naive group was 84%, of which 6% of patients achieved complete remission; the ORR of patients in the previously treated group was 61%, of which 7% of patients achieved complete remission. In addition, the average time for continued tumor shrinkage after serpatinib treatment exceeded 20 months, and most patients' tumors did not progress or worsen during follow-up.

Selpatinib also performs well in patients with advanced lung cancer with brain metastases. Clinical trials have shown that among patients with brain metastases treated with serpatinib, 85% of patients experienced shrinkage of intracranial tumors, and 7% of them achieved complete remission. In patients without brain metastases, serpatinib can also effectively prevent or delay the occurrence of new brain metastases.

Serpatinib also has good safety and tolerability, and its adverse reactions are relatively mild. Common adverse reactions include hypertension, diarrhea, fatigue, etc., and these adverse reactions can be effectively managed by adjusting dosage or other treatments. Serious adverse reactions are less common and mainly include pneumonia and drug allergy.

Selpatinib has been approved by many countries for the treatment of patients with RET fusion-positive advanced or metastatic non-small cell lung cancer. Its precise therapeutic mechanism targeting specific gene mutations makes treatment more effective, while reducing unnecessary toxic side effects and improving patients' quality of life. In addition, serpatinib is also undergoing clinical trials in other types of RET fusion-positive cancers and is expected to provide effective treatment options for more patients.

References:

https://www.cancer.gov/news-events/cancer-currents-blog/2023/selpercatinib-ret-lung-medullary-thyroid